Monthly Archives

August 2017

Inova Personalized Health Accelerator Names Michael Thomas as Director

By | News | No Comments

FAIRFAX, Va.Aug. 24, 2017 /PRNewswire/ — The Inova Personalized Health Accelerator (IPHA) announced today that health and biosciences industry veteran Michael Thomas has been appointed Director of the Accelerator. Prior to joining Inova, Michael was founder and CEO of Appian Partners, an Annapolis life sciences consulting practice. His med-tech experience has spanned several early stage, growth stage, and turn-around ventures as CEO of Appian Partners, ReGear Life Sciences, NuSomnea, Tanzen Medical, Mommy’s Medicine Cabinet, Appian Medical, iSonea, and NovaSom. He also served on the board of directors for AdvaMed and Circadiance. He started his career in the pharmaceutical industry with Merck & Company and GlaxoSmithKline. Michael earned a BS in Microbiology from Cornell University.

“Mike’s experience in raising over $125 million in venture capital, angel funding, and private equity combined with his leadership experience as a chief executive in startup and public companies will provide IPHA participants with outstanding guidance as they develop their company to meet the needs of health system markets,” said Todd Stottlemyer, CEO of the Inova Center for Personalized Health (ICPH). Michael will be one of four directors that support the operations and portfolio of IPHA. He joins Hooks Johnston and Pete Jobse, with a fourth director to be named in the future.

IPHA, a variation on the traditional accelerator model, is differentiated by rolling admissions; with a limit of no more than 6 companies at one time and customized programs that provide individual companies the capital investment, mentoring, and networking they need to accelerate the development and commercialization of their products. The program also affords companies direct access to the Inova Health System to validate innovations and demonstrate value.

The Inova Health System previously announced the formation of IPHAwhich will commence operations in the third quarter of 2017. IPHA provides qualified healthcare technology start-ups with a unique series of services to help them grow into sustainable businesses. These services include C-suite coaches, customized plans for commercialization, capital investment, and connections to potential customers. An announcement calling for applicants will be issued at the end of the summer.

About Inova Personalized Health Accelerator 

The Inova Personalized Health Accelerator is a unique program that provides C-suite coaches, customized plans, early stage capital, connections to strategic partners and later stage capital, and connections to customers for healthcare technology and services entrepreneurs.  This bespoke approach to enhance med-tech entrepreneurs’ efforts to accelerate new companies through the early stages of product design, capital formation and commercialization will serve as the foundation for a stronger healthcare ecosystem in the mid-Atlantic region. Additional program information is located at

About Inova 

Inova is a global leader in personalized health, which leverages precision medicine to predict, prevent and treat disease, enabling individuals to live longer, healthier lives. At Inova, we serve more than 2 million people each year from throughout the Washington, DC, metro area and beyond.

We are shaping the future of health through our integrated network of hospitals, primary and specialty care practices, emergency and urgent care centers, outpatient services and destination institutes.  Our commitment to health and wellness is further reflected in our sustainable practices. Inova is home to world-class researchers, expert medical specialists and renowned scientists, who are driving innovation to improve patient care, prevent disease and promote wellness. For more information, visit, or find Inova on FacebookTwitter and LinkedIn.

CONTACT: Kelly Schlageter, rel=”nofollow”>, 571-472-0200

View original content:

SOURCE Inova Health System

View Original Article »

Virginia Bio Elects New Officers for Board of Directors

By | News | No Comments

RICHMOND, Va.–(BUSINESS WIRE)–Virginia Bio, the premier statewide non-profit association of the life science industry in Virginia, elected Andrew J. Krouse to a two-year term as Chairman of the Board of Directors, during the annual meeting of the Board held at i.Lab at UVA.

“My priorities will be to increase access of Virginia companies to private investment, engender a richer active engagement of all of our members in our community, and better communicate the story of Virginia bioscience commercialization to policy makers and other stakeholders.”http://

Andrew Krouse, MALS, is the President & CEO of Cavion, Inc., a venture-backed pharmaceutical company in Charlottesville, developing best-in-class T-type calcium channel (Cav3) therapies that restore the brain’s natural rhythms and normal function in diseases that share a common pathophysiology, including movement disorders, epilepsy, and pain. Mr. Krouse has over a decade of biotech leadership experience as founder of Tau Therapeutics LLC, Xdynia LLC and Cavion, Inc. Mr. Krouse has served as a member of the Virginia Bio Board of Directors since 2011, most recently as Vice-Chairman.

“I look forward to working with my colleagues throughout industry and academia to keep this great organization going strong,” said Mr. Krouse. “My priorities will be to increase access of Virginia companies to private investment, engender a richer active engagement of all of our members in our community, and better communicate the story of Virginia bioscience commercialization to policy makers and other stakeholders.”

Alan Connor, President & CEO of Cadence Inc., Staunton, was elected as Vice-Chairman. Cadence Inc. is a full-service contract manufacturer and leading supplier of advanced products, technologies and services to medical device, life science, and industrial companies worldwide.

Ross Dunlap, CEO and a co-founder of Ceres Nanosciences, Prince William County, was elected Secretary. Among other things, Mr. Dunlap is directing the clinical development, validation, and market launch of a novel Lyme Antigen Test that will provide the most sensitive and accurate detection of Lyme disease.

The board also elected as a new Director Eric Paradise, who is a Senior Director in business development at MedImmune, the global biologics R&D arm of AstraZeneca.

Other officers and members of the Executive Committee of Virginia Bio Board are Crystal Icenhour, CEO Aperiomics, Ashburn, Immediate Past Chair; Jeff Conroy, CEO Embody LLC, Norfolk, Past Chair; Carrie Roth, CEO VA Bio+Tech Park, Richmond, Treasurer; and Jim Powers, CEO HemoShear, Charlottesville.

The complete list of Virginia Bio board members is at

About Virginia Bio

Virginia Bio is the premier statewide non-profit trade association for life sciences, promoting the considerable scientific and economic impact of the life sciences industry in the Commonwealth of Virginia. Virginia Bio is an advocate for innovation and entrepreneurship, and for the biopharmaceutical, and other health technology industries among federal, state and local policy-makers. Virginia Bio is the official state affiliate of BIO (the Biotechnology Innovation Organization), AdvaMed and MDMA (Medical Device Manufacturers Association), and works closely with PhRMA (Pharmaceutical Research and Manufacturers of America). To learn more, visit or follow Virginia Bio on Twitter at @VABio


Virginia Bio
Sherri Halloran, 804-643-6360
Vice President Membership and Programs


View Original Article »

Join our Mailing List